Anti-EGFRvIII chimeric antigen receptor T cell therapy - Marino Biotechnology

Drug Profile

Anti-EGFRvIII chimeric antigen receptor T cell therapy - Marino Biotechnology

Alternative Names: Anti-EGFRvIII CAR T cell therapy - Marino Biotechnology

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator Beijing Sanbo Brain Hospital; Marino Biotechnology
  • Developer Marino Biotechnology
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Epidermal growth factor receptor antagonists; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 01 Jul 2016 Phase-I clinical trials in Glioblastoma (Recurrent) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top